Get the Weekly Intelligence Brief — top committee picks every Sunday.
EWTX · NASDAQ · STOCK

Edgewise Therapeutics, Inc.

Healthcare Updated August 11, 2026
$44.30
52W $12.84 – $48.40
61/100
$4.77B
-24.0
0.28
AI Committee Verdict
Buy
61/100
Conviction: Moderate · 60% agreement · 5 analysts
Moderate

Is EWTX Bullish or Bearish?

Bullish. Innellis AI committee rates Edgewise Therapeutics, Inc. (EWTX) Buy with a composite score of 61/100 , based on 5 analysts with 60% agreement. Last updated August 11, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +14.08 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -5.92 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

Positive signals support the current rating — vix regime is low -- calm backdrop supports risk-taking. The committee sees sufficient evidence to maintain the constructive view.

Bull & Bear Case

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
  • Price-to-book of 5.0x prices in significant intangible value — Value
  • ROE of only -39.0% -- cheap may mean cheap for a reason — Value
  • Bollinger bandwidth of 23.8% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 11, 2026
Overall Committee Score
61/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 40%
of 192 Healthcare peers
Value Analyst neutral
43 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 5.0x prices in significant intangible value
Technical Analyst bullish
69 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Risk Analyst neutral
58 / 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 23.8% signals elevated volatility
Macro Analyst bullish
78 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Open Full Terminal →

Technical Analysis

RSI (14)
61.0
Neutral
MACD Histogram
0.348
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$31.06
Resistance
$48.36
Bollinger %B
0.83
Inside Bands
Price vs Moving Averages
EMA 9
$43.12 Above
EMA 21
$41.84 Above
EMA 50
$39.71 Above
EMA 200
$32.03 Above

Fundamental Analysis

Valuation
60
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio -24.0×
P/B Ratio 10.65×
PEG Ratio 1.37
Dividend Yield 0.00%
52W High $48.40
52W Low $12.84
Quality & Growth
ROE -3212.9%
ROA -3036.4%
Gross Margin 0.0%
Operating Margin 0.0%
Revenue Growth YoY
Debt / Equity 0.01
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -24.0 (inexpensive relative to a 15-40x range); Price-to-book of 10.6x; PEG ratio of 1.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -32.1%; Return on assets of -30.4%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 16.24 (healthy short-term liquidity); Debt-to-equity of 0.01; Free cash flow per share is negative (-1.48); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full EWTX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore EWTX Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime